Stay updated on PI3K/Akt Suppression vs MK-3475 in Glioblastoma Clinical Trial

Sign up to get notified when there's something new on the PI3K/Akt Suppression vs MK-3475 in Glioblastoma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the PI3K/Akt Suppression vs MK-3475 in Glioblastoma Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    2 days ago
    No Change Detected
  3. Check
    3 days ago
    No Change Detected
  4. Check
    4 days ago
    Change Detected
    Summary
    The study has expanded to include 13 locations, and the revision has been updated from v2.9.7 to v2.10.0.
    Difference
    0.4%
    Check dated 2024-07-23T14:24:43.000Z thumbnail image
  5. Check
    5 days ago
    No Change Detected
  6. Check
    11 days ago
    Change Detected
    Summary
    The website has been updated to Revision v2.9.7 from v2.9.6.
    Difference
    0.1%
    Check dated 2024-07-16T07:43:07.000Z thumbnail image
  7. Check
    25 days ago
    Change Detected
    Summary
    The value of Revision has been updated from v2.9.5 to v2.9.6, indicating a recent change in the webpage content related to the study evaluating the effectiveness of treatment for Glioblastoma / Gliosarcoma through the suppression of the PI3K/Akt pathway compared with MK-3475 (Pembrolizumab).
    Difference
    0.1%
    Check dated 2024-07-02T13:34:44.000Z thumbnail image
  8. Check
    30 days ago
    Change Detected
    Summary
    The value of Revision has been updated from v2.9.3 to v2.9.5, indicating a recent change in the webpage content related to the study evaluating the effectiveness of treatment for Glioblastoma / Gliosarcoma through the suppression of the PI3K/Akt pathway compared with MK-3475 (Pembrolizumab).
    Difference
    0.1%
    Check dated 2024-06-27T09:47:26.000Z thumbnail image
  9. Check
    31 days ago
    Change Detected
    Summary
    The value of Revision has been updated from v2.9.1 to v2.9.3, indicating a recent revision in the content of the webpage.
    Difference
    0.1%
    Check dated 2024-06-26T08:40:13.000Z thumbnail image
  10. Check
    32 days ago
    Change Detected
    Summary
    The value 'Show more Show more Revision: v2.9.0' has been updated to 'Show less Genetic and Rare Diseases Information Center resources: Glioblastoma Gliosarcoma Glioma Neuroepithelioma Drug Information available for: Pembrolizumab FDA Drug and Device Resources Show less'. This change indicates a shift in the displayed content from showing more details to showing less information related to genetic and rare diseases, specifically focusing on resources for Glioblastoma, Gliosarcoma, Glioma, Neuroepithelioma, and Drug Information for Pembrolizumab.
    Difference
    23%
    Check dated 2024-06-25T08:22:27.000Z thumbnail image

Stay in the know with updates to PI3K/Akt Suppression vs MK-3475 in Glioblastoma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the PI3K/Akt Suppression vs MK-3475 in Glioblastoma Clinical Trial page.